StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
8
Publishing Date
2023 - 08 - 08
1
2023 - 03 - 28
1
2023 - 01 - 27
1
2022 - 09 - 10
1
2021 - 11 - 29
1
2021 - 06 - 04
1
2021 - 04 - 23
1
2021 - 04 - 07
1
Sector
Health technology
8
Tags
Acquisition
8
Agreement
9
Alliances
21
Antibody
14
Application
22
Approval
48
Biotech-bay
15
Cancer
107
Cell
22
Cell carcinoma
11
Chmp
17
Clinical-trials-phase-ii
15
Clinical-trials-phase-iii
20
Collaboration
34
Conference
18
Disease
22
Drug
63
Earnings
24
Europe
16
Events
24
Expected
9
Fda
20
Financial
21
Financial results
17
Food
24
Genetown
11
Global
67
Growing
13
Growth
35
Health
9
Immunotherapy
17
Int230
9
Iot
11
License
12
Lung
16
Market
125
N/a
325
Nivolumab
60
Opdivo
33
People
13
Pharm-country
67
Pharmaceutical
13
Pharmaceuticals
9
Phase 1
10
Phase 2
15
Phase 3
12
Positive
27
Product-news
14
Reach
12
Renal
11
Report
67
Research
80
Results
64
Solid tumors
10
Study
9
Therapeutics
48
Therapy
65
Treatment
93
Trial
48
Update
10
Entities
Abbvie inc.
2
Amgen inc.
7
Bausch health companies inc.
2
Bristol-myers squibb company
8
Eli lilly and company
2
Glaxosmithkline plc
2
Johnson & johnson
2
Novartis ag
2
Symbols
ABBV
7
ADTX
3
ALDX
1
ALPMF
1
ALPMY
1
AMGN
12
ANAB
5
ARQT
22
AZN
3
AZNCF
2
BGNE
2
BHC
4
BMY
8
CANF
14
DICE
2
DMTK
1
ENTX
1
EVLO
9
GLAXF
1
GSK
4
IMUX
2
INCY
4
IVA
1
JNJ
24
LABP
1
LLY
14
NBY
1
NKTR
1
NOVN
2
NVO
1
NVS
7
NVSEF
3
NXGL
1
PFE
1
PRGO
2
PTGX
11
RMED
1
ROIV
2
RVP
1
RVPH
1
SNGX
6
SNY
8
SNYNF
7
TMO
1
UCBJF
1
UCBJY
1
VTRS
1
VTVT
3
VTYX
3
Exchanges
Nasdaq
7
Nyse
8
Crawled Date
2023 - 08 - 08
1
2023 - 03 - 28
1
2023 - 01 - 27
1
2022 - 09 - 10
1
2021 - 11 - 29
1
2021 - 06 - 04
1
2021 - 04 - 23
1
2021 - 04 - 07
1
Crawled Time
08:00
1
08:20
1
12:30
1
13:00
3
18:00
1
21:00
1
Source
www.biospace.com
6
www.prnewswire.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Psoriasis
symbols :
Bmy
save search
Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis
Published:
2023-08-08
(Crawled : 13:00)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-19.2%
|
O:
0.36%
H:
0.21%
C:
-0.87%
reveal
psoriasis
living
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Published:
2023-03-28
(Crawled : 13:00)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-28.22%
|
O:
0.01%
H:
0.75%
C:
0.18%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
15.31%
|
O:
0.1%
H:
0.71%
C:
0.62%
approval
psoriasis
treatment
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Published:
2023-01-27
(Crawled : 13:00)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-33.06%
|
O:
0.0%
H:
0.63%
C:
-0.74%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
7.11%
|
O:
-0.0%
H:
0.25%
C:
-0.48%
treatment
chmp
psoriasis
positive
U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
Published:
2022-09-10
(Crawled : 08:20)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
Email alert
Add to watchlist
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
Email alert
Add to watchlist
treatment
drug
psoriasis
food
plague
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
Published:
2021-11-29
(Crawled : 12:30)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-13.14%
|
O:
-0.24%
H:
0.0%
C:
0.0%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
33.24%
|
O:
-1.18%
H:
1.16%
C:
0.49%
psoriasis
food
treatment
europe
application
drug
plague
Global $53 Bn Psoriasis Drugs Markets 2021-2030: Biologic Drugs, Small-Molecule Systemic Drugs, Topical Therapies, TNF-Alpha, PDE4, & Interleukin Inhibitors, Oral, Parenteral, Topical
Published:
2021-06-04
(Crawled : 21:00)
- prnewswire.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
Email alert
Add to watchlist
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
Email alert
Add to watchlist
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
Email alert
Add to watchlist
BHC
|
$8.56
0.35%
0.0%
2M
|
Health Technology
|
Email alert
Add to watchlist
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
Email alert
Add to watchlist
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
Email alert
Add to watchlist
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
Email alert
Add to watchlist
drug
psoriasis
therapy
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
Published:
2021-04-23
(Crawled : 18:00)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-26.33%
|
O:
-0.03%
H:
0.95%
C:
-0.44%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
7.04%
|
O:
-0.03%
H:
1.24%
C:
0.8%
positive
phase 3
psoriasis
Global Psoriasis Drugs Market to Reach $53,210.6 Million by 2030, says P&S Intelligence
Published:
2021-04-07
(Crawled : 08:00)
- prnewswire.com
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
13.88%
|
O:
0.02%
H:
0.34%
C:
-0.09%
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
-9.33%
|
O:
0.1%
H:
0.45%
C:
0.04%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
13.44%
|
O:
0.58%
H:
0.28%
C:
-0.47%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
300.55%
|
O:
0.05%
H:
0.15%
C:
-0.32%
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-21.17%
|
O:
0.05%
H:
0.85%
C:
0.08%
BHC
|
$8.56
0.35%
0.0%
2M
|
Health Technology
|
-72.6%
|
O:
-0.1%
H:
1.33%
C:
1.09%
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
59.23%
|
O:
0.14%
H:
0.57%
C:
-0.3%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
9.6%
|
O:
-0.37%
H:
0.83%
C:
-0.02%
drug
psoriasis
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.